Edgar Lomax Co. VA Has $19.46 Million Holdings in Gilead Sciences, Inc. $GILD

Edgar Lomax Co. VA lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 175,300 shares of the biopharmaceutical company’s stock after selling 52,355 shares during the quarter. Gilead Sciences makes up about 1.5% of Edgar Lomax Co. VA’s holdings, making the stock its 27th biggest holding. Edgar Lomax Co. VA’s holdings in Gilead Sciences were worth $19,458,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter worth $26,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences in the 2nd quarter worth about $30,000. MTM Investment Management LLC lifted its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares in the last quarter. Kilter Group LLC acquired a new stake in Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Millstone Evans Group LLC grew its stake in Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 118 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on GILD. Argus increased their price target on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. HSBC increased their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada lifted their price objective on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.72.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the sale, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares in the company, valued at $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 309,280 shares of company stock valued at $43,935,470 in the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Down 2.1%

GILD stock opened at $145.14 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a fifty day simple moving average of $137.91 and a 200 day simple moving average of $125.56. The firm has a market cap of $180.18 billion, a PE ratio of 21.44, a PEG ratio of 1.94 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the business posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.